AU2021247879B2 - Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent - Google Patents

Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent Download PDF

Info

Publication number
AU2021247879B2
AU2021247879B2 AU2021247879A AU2021247879A AU2021247879B2 AU 2021247879 B2 AU2021247879 B2 AU 2021247879B2 AU 2021247879 A AU2021247879 A AU 2021247879A AU 2021247879 A AU2021247879 A AU 2021247879A AU 2021247879 B2 AU2021247879 B2 AU 2021247879B2
Authority
AU
Australia
Prior art keywords
cells
culture
mesenchymal stem
stem cells
laminin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021247879A
Other languages
English (en)
Other versions
AU2021247879A1 (en
Inventor
Takefumi Ishidao
Itsunari Minami
Chugo RINOIE
Yasutomo YANAGITA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Exosome Therapeutics Inc
Original Assignee
Cell Exosome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Exosome Therapeutics Inc filed Critical Cell Exosome Therapeutics Inc
Priority to AU2022259729A priority Critical patent/AU2022259729B2/en
Publication of AU2021247879A1 publication Critical patent/AU2021247879A1/en
Application granted granted Critical
Publication of AU2021247879B2 publication Critical patent/AU2021247879B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2021247879A 2020-03-31 2021-03-26 Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent Active AU2021247879B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022259729A AU2022259729B2 (en) 2020-03-31 2022-10-25 Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020063408 2020-03-31
JP2020-063408 2020-03-31
PCT/JP2021/013099 WO2021200744A1 (ja) 2020-03-31 2021-03-26 増殖細胞の生産方法、細胞生産物の生産方法、間葉系幹細胞集団およびその生産方法、幹細胞の培養上清およびその生産方法、並びに治療剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022259729A Division AU2022259729B2 (en) 2020-03-31 2022-10-25 Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent

Publications (2)

Publication Number Publication Date
AU2021247879A1 AU2021247879A1 (en) 2022-11-03
AU2021247879B2 true AU2021247879B2 (en) 2025-04-24

Family

ID=77930052

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021247879A Active AU2021247879B2 (en) 2020-03-31 2021-03-26 Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent
AU2022259729A Active AU2022259729B2 (en) 2020-03-31 2022-10-25 Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022259729A Active AU2022259729B2 (en) 2020-03-31 2022-10-25 Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent

Country Status (8)

Country Link
US (1) US20230172992A1 (https=)
EP (2) EP4130240A4 (https=)
JP (3) JPWO2021200744A1 (https=)
CN (2) CN115362252A (https=)
AU (2) AU2021247879B2 (https=)
CA (2) CA3177567A1 (https=)
TW (2) TW202204605A (https=)
WO (1) WO2021200744A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2021200744A1 (https=) * 2020-03-31 2021-10-07
EP4324914B1 (en) * 2021-06-11 2026-03-18 Fullstem Co., Ltd. Exosome production promoting agent and exosome production promoting method
JP7763475B2 (ja) * 2021-12-24 2025-11-04 株式会社日本バイオセラピー研究所 培養上清を生産する方法
WO2024019080A1 (ja) * 2022-07-19 2024-01-25 国立大学法人 長崎大学 血管内皮増殖因子を高発現する臍帯由来間葉系細胞の製造方法、および肺疾患治療用医薬組成物
JP7851648B2 (ja) * 2022-12-23 2026-04-27 Ｃｅｌｌ Ｅｘｏｓｏｍｅ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 間葉系幹細胞又はその培養上清の利用
WO2025151805A1 (en) * 2024-01-10 2025-07-17 Biotech Therapeutics, LLC Mesenchymal stromal cell-derived extracellular vesicle-exosomes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3009502A1 (en) * 2013-06-12 2016-04-20 Osaka University Cell culture equipment coated with laminin fragments in dry state
EP3170892A1 (en) * 2014-07-16 2017-05-24 Osaka University Method for enhancing activity of laminin fragment cell culture substrate

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378612A (en) * 1990-05-11 1995-01-03 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Culture medium for production of recombinant protein
JPH05207875A (ja) * 1992-01-28 1993-08-20 Mitsui Toatsu Chem Inc 無血清培地
AU680909B2 (en) * 1994-04-06 1997-08-14 Immunex Corporation Interleukin-15
JPH10179147A (ja) * 1996-12-27 1998-07-07 Ishikawajima Harima Heavy Ind Co Ltd 植物細胞培養方法および二次代謝物高生産性植物細胞
EP1930413B1 (en) * 2005-08-23 2011-01-12 Oriental Yeast Co., Ltd. Technique for culture of mesenchymal stem cell utilizing laminin-5
AU2007294731B2 (en) * 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
WO2010040262A1 (zh) * 2008-10-10 2010-04-15 深圳市嘉天源生物科技有限公司 分离动物胚胎间质性干细胞并提取其分泌物的方法
WO2012137970A1 (ja) 2011-04-08 2012-10-11 国立大学法人大阪大学 改変ラミニンおよびその利用
WO2012145682A1 (en) * 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
CN104884468B (zh) 2012-12-28 2018-08-31 国立大学法人大阪大学 附加有胶原结合性分子的改造层粘连蛋白及其利用
CN104651305A (zh) * 2015-02-13 2015-05-27 沈阳澔源生物科技有限公司 一种利用脐带间充质干细胞获取生物活性蛋白的方法
JP6849957B2 (ja) * 2015-11-10 2021-03-31 国立大学法人京都大学 ラミニンフラグメント含有培地を用いる細胞培養方法
RU2742828C2 (ru) * 2016-03-09 2021-02-11 Авита Интернэшнл Лтд. Применение стволовых клеток, экспрессирующих мезенхимальные и нейрональные маркеры, и их композиций для лечения неврологических заболеваний (варианты)
AU2018228352B2 (en) * 2017-02-28 2024-08-01 Centre Hospitalier Régional Universitaire De Nancy Mesenchymal stem cells obtained from Wharton's jelly for the treatment of sepsis
JP6469287B1 (ja) * 2018-06-22 2019-02-13 株式会社 バイオミメティクスシンパシーズ 中空糸細胞培養装置，細胞培養方法，培養上清の製造方法
JPWO2021200744A1 (https=) * 2020-03-31 2021-10-07

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3009502A1 (en) * 2013-06-12 2016-04-20 Osaka University Cell culture equipment coated with laminin fragments in dry state
EP3170892A1 (en) * 2014-07-16 2017-05-24 Osaka University Method for enhancing activity of laminin fragment cell culture substrate

Also Published As

Publication number Publication date
AU2021247879A1 (en) 2022-11-03
EP4155389A3 (en) 2023-07-12
JPWO2021200744A1 (https=) 2021-10-07
EP4130240A1 (en) 2023-02-08
CA3177567A1 (en) 2021-10-07
EP4130240A4 (en) 2024-05-08
EP4155389A2 (en) 2023-03-29
CN116179480A (zh) 2023-05-30
TW202311526A (zh) 2023-03-16
AU2022259729B2 (en) 2025-05-01
AU2022259729A1 (en) 2022-12-01
JP2024015245A (ja) 2024-02-01
US20230172992A1 (en) 2023-06-08
JP2022181218A (ja) 2022-12-07
WO2021200744A1 (ja) 2021-10-07
TW202204605A (zh) 2022-02-01
CN115362252A (zh) 2022-11-18
CA3173721A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
AU2022259729B2 (en) Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent
Drobiova et al. Wharton’s jelly mesenchymal stem cells: a concise review of their secretome and prospective clinical applications
JP6920644B2 (ja) 幹細胞の免疫制御作用を調節する方法
Sordi et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets
JP7048977B2 (ja) コロニー形成培地及びその使用
JP7549355B2 (ja) 間葉系間質細胞を拡大するための方法
US20240294873A1 (en) Methods for the long-term expansion of granulocyte-macrophage progenitors and applications thereof
JPWO2017188403A1 (ja) Ｃｄ２０１、ｃｄ４６、ｃｄ５６、ｃｄ１４７及びｃｄ１６５からなる群より選択される少なくとも１種の細胞表面マーカーを発現する間葉系幹細胞及びその調製方法、並びに上記間葉系幹細胞を含む医薬組成物及びその調製方法
CN104204192A (zh) 间充质干细胞调理的基质及其产生和使用方法
EP2294183A2 (en) Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
KR20100035648A (ko) 체외 배양 및 증식 자기재생성 집락 형성 세포를 이용한 질환 및 장애 치료방법
CN110898078B (zh) 一种间充质干细胞分泌因子的制备及应用
JP2020072725A (ja) 向上された臍帯由来付着型幹細胞、その製造方法及びその用途
CA2727535A1 (en) Paracrine signals from mesenchymal feeder cells and regulating expansion and differentiation of hepatic progenitors using same
US20240117301A1 (en) Method for producing proliferating cells, method for producing cell product, mesenchymal stem cell population and method for producing same, culture supernatant of stem cells and method for producing same, and therapeutic agent
JP2024516172A (ja) 間葉系前駆体又は幹細胞を使用する急性呼吸窮迫症候群（ａｒｄｓ）を治療するための方法
JP6695795B2 (ja) 造血細胞の増殖ペプチドおよびその用途
US20130259837A1 (en) Compositions and Methods of Using Living and Non-Living Bioactive Devices with Components Derived From Self-Renewing Colony Forming Cells Cultured and Expanded In Vitro
NZ793106A (en) Method of producing proliferated cells, method of producing cell product, mesenchymal stem cell population and method of producing same, culture supernatant of stem cells and method of producing same, and therapeutic agent
HK40089499A (zh) 增殖细胞和细胞生产物的生产法、间充质干细胞群和干细胞培养上清及其生产法、治疗剂
HK40084736A (en) Method for producing proliferating cells, method for producing cell product, mesenchymal stem cell population and method for producing same, culture supernatant of stem cells and method for producing same, and therapeutic agent
JP2022501045A (ja) ヒト多能性成人幹細胞
WO2022259721A1 (ja) 間葉系幹細胞の製造方法
Moore The hematopoietic system and hematopoiesis
Pamulang Upscale production of canine adipose-derived mesenchymal stem cell-derived exosomes for wound healing in vitro

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ METHOD OF PRODUCING PROLIFERATED CELLS, METHOD OF PRODUCING CELL PRODUCT, MESENCHYMAL STEM CELL POPULATION AND METHOD OF PRODUCING SAME, CULTURE SUPERNATANT OF STEM CELLS AND METHOD OF PRODUCING SAME, AND THERAPEUTIC AGENT

FGA Letters patent sealed or granted (standard patent)